Compare Adaptive Biotechnologies Corp (ADPT) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Matson Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.98 (market cap $4.04B), while Matson Inc trades at $213.8 (market cap $6.11B). The key difference: Matson Inc is the larger of the two by market cap, and Matson Inc pays a 0.74% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MATX | |
|---|---|---|
Market Cap | $4.04B | $6.11B |
Sector | Health | Technology |
52-Week High | $25.45 | $223.55 |
52-Week Low | $12.30 | $88.05 |
Enterprise Value | $4.10B | $6.71B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Matson (MATX) trades at $212.05, up 1.61% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.27 surpassing expectations. Revenue and net income are trending upward, supported by a robust China service and resilient consumer demand. The company's valuation ratios, including a P/E of 13.79 and EV/EBITDA of 7.78, appear reasonable relative to earnings growth.
The outlook for MATX is positive, driven by earnings momentum and a favorable analyst consensus with a $265 price target implying significant upside. Key opportunities include continued trade flow strength and dividend growth, while risks involve Trans-Pacific trade volatility and broader economic pressures. The stock presents a compelling case for growth-oriented investors seeking exposure to niche shipping services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
